In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Pharmaceutical
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Pharmaceutical
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
Pharmaceutical
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Pharmaceutical
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
Pharmaceutical
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Pharmaceutical
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Pharmaceutical
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Pharmaceutical
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Pharmaceutical
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
Pharmaceutical
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Pharmaceutical
A new research paper concluding that the use of Inpefa (sotagliflozin) for the treatment of patients hospitalized for heart failure (HF) and suffering from co- morbid diabetes leads to significant positive impact on provider health system financial outcomes. 18 July 2024
Pharmaceutical
Boehringer Ingelheim has entered partnership with AI company Brainomix for a collaborative program of activity to improve the care of patients with fibrosing lung disease in the USA. 18 July 2024
Pharmaceutical
Swiss pharma giant Novartis (NOVN: VX) has reported an impressive second quarter, with net sales increasing by 11% and core operating income rising by 19% to reach $5 billion. 18 July 2024
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday announced it has approved two new medicines for use in Great Britain. 18 July 2024
Pharmaceutical
Shares in US healthcare giant Johnson & Johnson jumped by 3% during Wednesday morning’s trading. 17 July 2024
Pharmaceutical
Trade association has called on the authorities of Russia to make adjustments for the methods of calculation of the initial maximum price of contracts (IMCP) for public procurements of drugs. 17 July 2024
Pharmaceutical
The Phase III ARANOTE trial met its primary endpoint, significantly increasing radiological progression-free survival (rPFS) with darolutamide + androgen deprivation therapy (ADT) compared to placebo plus ADT, says Bayer. 17 July 2024
Pharmaceutical
As the World Health Organization (WHO) calls for advancements to combat serious infections, one American firm is raising awareness about its work on nanoparticles. 17 July 2024
Pharmaceutical
Tokyo-based Renalys Pharma, a late-stage clinical biopharmaceutical company, has successfully completed a $43.5 million series A financing. 17 July 2024
Pharmaceutical
Full-Life Technologies says it has entered into a license agreement with South Korea’s SK Biopharmaceuticals. 17 July 2024
Pharmaceutical
US oncology specialist Scorpion Therapeutics has closed a $150 million Series C financing. 17 July 2024
Pharmaceutical
Lexicon Pharmaceuticals announced that the US Food and Drug Administration (FDA) has acknowledged the resubmission of its New Drug Application (NDA) for Zynquista (sotagliflozin) 17 July 2024
Pharmaceutical
Japanese firm Kissei Pharmaceutical (OTC: KSPHF) has announced promising results from two domestic Phase III trials of its GnRH receptor antagonist linzagolix. 17 July 2024
Pharmaceutical
US health technology assessor the Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of Ohtuvayre (ensifentrine). 17 July 2024
Pharmaceutical
Swedish drugmaker Orexo (STO:ORX) has been struck by an unexpected delay in its bid to register a high-dose naloxone rescue medication in the USA. 17 July 2024
Pharmaceutical
A licensing deal between CSL Vifor and Akebia Therapeutics has been terminated, as the commercial launch of Vafseo (vadadustat) gets underway. 16 July 2024
Pharmaceutical
US pharma major AbbVie has announced that Steve Hopkinson has been appointed as vice president and general manager, UK. 16 July 2024
Pharmaceutical
Sionna Therapeutics today announced it has acquired exclusive worldwide rights to develop and commercialize multiple clinical-stage compounds through a license agreement with pharma major AbbVie. 16 July 2024
Pharmaceutical
Privately-held inflammatory disease specialist SFA Therapeutics has appointed James Kirwin as chief operating officer. 16 July 2024
Pharmaceutical
Indian firm Mankind Pharma (BSE: 543904) and Japanese pharma major Takeda Pharmaceutical (TYO: 4502) have inked a non-exclusive patent license agreement related to vonoprazan. 16 July 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze